Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Dellanna

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Clinical Nephrology|September 6, 2012
Efficacy and safety of lanthanum carbonate in German patients on dialysisFrank Dellanna, Helmut Reichel, Frank Seibt
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 11, 2017
Early low-dose erythropoiesis-stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo-controlled trialDanilo Fliser, Frank Dellanna, Michael Koch, et al.
Clinical Drug Investigation|March 4, 2018
Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?David Goldsmith, Frank Dellanna, Martin Schiestl, et al.
Proteomics. Clinical Applications|December 12, 2017
Detection of the Human Anti-ActRII Antibody Bimagrumab in Serum by Means of Affinity Purification, Tryptic Digestion, and LC-HRMSKatja Walpurgis, Andreas Thomas, Frank Dellanna, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|November 22, 2011
Monthly continuous erythropoietin receptor activator treatment maintains stable hemoglobin levels in routine clinical management of hemodialysis patientsThomas Weinreich, Frank Leistikow, Hagen-Georg Hartmann, et al.
Drug Design, Development and Therapy|January 4, 2018
HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experienceFrank Dellanna, David Goldsmith, Andriy Krendyukov, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 5, 2013
The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized studyFrancesco Locatelli, Goce Spasovski, Nada Dimkovic, et al.
Critical Reviews in Oncology/Hematology|December 8, 2022
Epoetin alfa biosimilar (HX575): A review of 15 years' post-approval clinical experiencePere Gascón, David Goldsmith, Matti Aapro, et al.
Drug Testing and Analysis|October 1, 2024
Long-Term Excretion of Roxadustat in UrineTim Sobolevsky, Matthew Fedoruk, Frank Dellanna, et al.
Journal of Separation Science|November 19, 2015
Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometryAndreas Thomas, Christian Görgens, Sven Guddat, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Clinical Nephrology|September 6, 2012
Efficacy and safety of lanthanum carbonate in German patients on dialysisFrank Dellanna, Helmut Reichel, Frank Seibt
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 11, 2017
Early low-dose erythropoiesis-stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo-controlled trialDanilo Fliser, Frank Dellanna, Michael Koch, et al.
Clinical Drug Investigation|March 4, 2018
Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?David Goldsmith, Frank Dellanna, Martin Schiestl, et al.
Proteomics. Clinical Applications|December 12, 2017
Detection of the Human Anti-ActRII Antibody Bimagrumab in Serum by Means of Affinity Purification, Tryptic Digestion, and LC-HRMSKatja Walpurgis, Andreas Thomas, Frank Dellanna, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|November 22, 2011
Monthly continuous erythropoietin receptor activator treatment maintains stable hemoglobin levels in routine clinical management of hemodialysis patientsThomas Weinreich, Frank Leistikow, Hagen-Georg Hartmann, et al.
Drug Design, Development and Therapy|January 4, 2018
HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experienceFrank Dellanna, David Goldsmith, Andriy Krendyukov, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 5, 2013
The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized studyFrancesco Locatelli, Goce Spasovski, Nada Dimkovic, et al.
Critical Reviews in Oncology/Hematology|December 8, 2022
Epoetin alfa biosimilar (HX575): A review of 15 years' post-approval clinical experiencePere Gascón, David Goldsmith, Matti Aapro, et al.
Drug Testing and Analysis|October 1, 2024
Long-Term Excretion of Roxadustat in UrineTim Sobolevsky, Matthew Fedoruk, Frank Dellanna, et al.
Journal of Separation Science|November 19, 2015
Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometryAndreas Thomas, Christian Görgens, Sven Guddat, et al.
Pageof 3